The role of RAGE in the diabetic neuropathy

• Authors: Juranek Judyta , Banach Marta
• Languages of publication: EN

Keywords

EN

diabetic neuropathy; neurodegeneration; RAGE

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2015
• Issue: 4
• Pages: 316-318

Contributors

author

Juranek Judyta

author

Banach Marta

References

• Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy.Diab Metab Res Rev 2012; 28(Suppl. 1): 8–14.
• Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia 2005; 48(5): 805–807.
• Manigrasso MB, Juranek J, Ramasamy R, et al. Unlocking the biology of RAGE in diabetic microvascular complications. Trends in endocrinology and metabolism: TEM 2014; 25(1): 15–22.
• Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83(11): 876–886.
• Schmidt AM, Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Frontiers in Bioscience: a journal and virtual library 2001; 6:D1151–D1160.
• Sasaki N, Takeuchi M, Chowei H, et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002; 326(2): 117–120.
• Teismann P, Sathe K, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging 2012; 33(10): 2478–2490.
• Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, abeta accumulation,and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB 2010; 24(4): 1043–1055.
• Anzilotti S, Giampa C, Laurenti D, et al. Immunohistochemical localization of receptor for advanced glycation end (RAGE) productsin the R6/2 mouse model of Huntington’s disease. Brain Res Bull 2012; 87(2–3): 350–358.
• Sousa MM, Du Yan S, Fernandes R, et al. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001; 21(19): 7576–78
• Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. JCI 2004; 114(12): 1741–1751.
• Haslbeck KM, Bierhaus A, Erwin S, et al. Receptor for advanced glycation endproduct (RAGE) – mediated nuclear factor-kappaBactivation in vasculitic neuropathy. Muscle Nerve 2004; 29(6): 853–860.
• Witzke KA, Vinik AI, Grant LM, et al. Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diab Care 2011; 34(7):1617–1621.
• Juranek JK, Geddis MS, Song F, et al. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice.Diabetes 2013; 62(3): 931–943.
• Cardoso I, Brito M, Saraiva MJ. Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloidpolyneuropathy V30M TTR-related. Dis Markers 2008; 25(1): 37–47.
• Casula M, Iyer AM, Spliet WG, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011; 179: 233–243.
• Abu El-Asrar AM, Nawaz MI, Siddiquei MM, et al. High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. Mediat Inflamm 2013; 2013:863036.
• Pietkiewicz J, Seweryn E, Bartys A, et al. Receptors for advanced glycation end products and their physiological and clinical significance.Post Hig Med Dosw (Online) 2008; 62: 511–523.
• Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. JCI 1995; 96(3): 1395.
• Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84(5): 489–497.
• Lee EJ, et al, Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. FASEB J 2015; 29(8): 3506–3514.
• Jandeleit-Dahm KA, Lassila M, Allen TJ. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease:interventional studies. Ann N Y Acad Sci 2005; 1043: 759–766.
• Yang WI, et al. Blocking the receptor for advanced glycation end product activation attenuates autoimmune myocarditis. Circ J 2014; 78(5): 1197–1205.
• Iwamoto H, et al. Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med 2014; 14: 68.
• . Santilli F, et al. Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet//coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. Vascul Pharmacol 2015; 72: 16–24.
• Jensen LJ, Flyvbjerg A, Bjerre M. Soluble receptor for advanced glycation end product: a biomarker for acute coronary syndrome.Biomed Res Int 2015; 2015: 815–942.
• Wang J, et al. Genetic polymorphisms of RAGE and risk of ulcerative colitis in a C hinese population. Immunol Lett 2015 (Epub ahead of print).
• Ilzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 120(2): 119–122.
• Juranek JK, Aleshin A, Rattigan EM, et al. Morphological changes and immunohistochemical expression of RAGE and its ligands in the sciatic nerve of hyperglycemic pig (Sus Scrofa). Biochem Insights 2010; 3: 47–59.
• Juranek JK, Kothary P, Mehra A, et al. Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies. Brain Behav 2013; 3(6): 701–709.
• Bekircan-Kurt CE, Uceyler N, Sommer C. Cutaneous activation of rage in nonsystemic vasculitic and diabetic neuropathy. Muscle Nerve 2014; 50: 377–383.